Deliver Consulting Limited | Back to main site
More

Program Overview

In recent years, targeted protein degradation (TPD) technology has emerged as a groundbreaking approach in drug discovery. By harnessing the ubiquitin-proteasome system or lysosomal pathways, protein degraders (e.g., PROTACs, molecular glues, and LYTACs) selectively induce the degradation of disease-related proteins, offering novel solutions for traditionally "undruggable" targets. 

Although TPD technology has demonstrated broad application prospects in multiple fields, several challenges remain to be overcome. These include improving degradation efficiency and specificity, reducing off-target effects, and ensuring in vivo safety. Additionally, the clinical translation of TPD faces numerous hurdles, such as drug stability, pharmacokinetic properties, and potential long-term toxicity.

With several Degraders advancing into clinical trials, the industry urgently needs interdisciplinary collaboration to drive technological innovation and standardization. In Return, TPD2026 Targeted Protein Degradation Forum will bring together academia and industry leaders to explore cutting-edge advancements, technical bottlenecks, and future directions in TPD, providing strategic insights and a collaborative platform to accelerate the development of next-generation protein degradation therapeutics.


More

2026 Speaker Committee

  • Takashi Owa

    Senior Corporate Group Officer
    Eisai Co., Ltd.

    More>

  • Victor Guallar

    ICREA Professor
    Barcelona Supercomputing Center & Nostrum Biodiscovery

    More>

  • Itsuro Nagase

    Senior Vice President, Head of Primary Focus Lead – Targeted Protein Degradation
    Astellas Pharmaceutical

    More>

  • Leo Fu

    Co-Founder, CTO
    GluBio Pharmaceutical

    More>

  • Wu Du

    SVP
    Hinova Therapeutics

    More>

  • Chang Hoon Ji

    Research Associate Professor/Executive Director
    Seoul National University, Cellular Degradation Biology Center/ AutotacBio, R&D Institute

    More>

  • Yong Guo

    CMO/SVP
    Polymed Biopharmaceuticals

    More>

  • Suman Shrestha

    Postdoctoral Researcher
    University of Toronto

    More>

Program Key Discussions

  • The Application and Development Strategy of Targeted Protein Degradation Technology
  • Novel Targeted Protein Degradation Technologies and Drug Discovery
  • Cutting Edge Drug Design and Evaluation
  • Discovery and Application of Novel Ligase Ligands
  • Translational and Clinical Development
  • CMC Development and Commercialization Strategies
  • Development and Exploration of Next-Generation Targeted Protein Degraders

Who would Attend

Approximately 350 professionals are expected to participate in the TPD2025 Targeted Protein Degradation Forum in China. Participants are mainly from targeted protein degradation technology research, innovative drug development companies, research institutes. The main positions include:

  • Management and Head of R&D
  • Researchers of Universities and Scientific Research Institutions
  • Early Stage Research, Technology Development and External Innovation
  • Medicinal Chemistry Research
  • Translational and Clinical Development
  • Preclinical and Clinical Research
  • CMC and Quality Control
  • Investment and Project Management
  • Business and Market Development